FRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, todayFRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, today

AllyGPO and BioCareSD Welcome Retina Associates of Cleveland, Highlighting the Market Need for New Transparent, Technology-Forward Options

2026/01/16 21:32
4 min read

FRISCO, Texas and TEMPE, Ariz., Jan. 16, 2026 /PRNewswire/ — AllyGPO® and BioCareSD®, a strategic partnership serving community-based specialty practices, today announced that Retina Associates of Cleveland, Inc (RACI) has selected BioCareSD for specialty distribution (SD) and AllyGPO for group purchasing organization (GPO) services. This relationship expands AllyGPO and BioCareSD’s growing national footprint in community retina and reflects increasing demand for alternative GPO and SD options that offer more transparent, technology-enabled drug management.

Founded in 1974 and celebrating more than 50 years of patient care, RACI is widely regarded as one of Ohio’s premier retina specialty practices. The practice is known for its leadership in clinical research and expertise in advanced treatments for age-related macular degeneration, diabetic retinopathy, retinal tears and detachments, and other complex retinal conditions.

“Maintaining our independence is central to how RACI cares for patients, and we value partners who support this,” said President of RACI David G. Miller, MD. “BioCareSD and AllyGPO, through consistent actions and collaboration, have demonstrated their genuine commitment to preserving community retina practice independence in meaningful, practical ways. Choosing to partner with them enables RACI to better manage day-to-day operational and financial demands while securing long-term resilience with more efficient workflows and greater visibility from data-driven analytics.”

AllyGPO and BioCareSD provide RACI with high-touch specialty distribution and GPO services designed specifically for modern community retina practices. Key considerations in RACI’s decision included supply reliability, transparency in drug pricing, more timely, accurate GPO contract rebates, and responsive, consultative support from a dedicated retina team that works closely with clinical and administrative teams.

Another differentiator was AllyGPO and BioCareSD’s technology-forward approach, including AllyIQ®, AllyGPO’s comprehensive specialty drug management platform. By integrating data from practices’ core operational systems and BioCareSD’s ordering site, AllyIQ supports informed decision making with clear, actionable insights into purchasing, inventory, and utilization.

“RACI exemplifies the kind of physician-led practice that AllyGPO was built to serve,” remarked Brian Ansay, CEO of AllyGPO. “Our role as a GPO is to provide insight and hands-on support that helps members navigate complexity, confidently make data-driven decisions, and firmly remain in control of their future.”

“Retina Associates of Cleveland is a highly respected practice with a longstanding reputation for clinical excellence and physician leadership,” said Jennifer Waters, SVP of Retina at BioCareSD. “Their decision to partner with us reinforces that the market is seeking more transparent, flexible, and technology-enabled distribution and GPO partners built specifically around the needs of community retina practices.” 

The addition of RACI reflects AllyGPO and BioCareSD’s continued growth in community retina, as practices seek support in navigating rising drug costs, payer pressures, new biosimilar introductions, increasing administrative complexity, and distributors’ acquisition of practices. To learn more, visit www.NewRetinaPartner.com.

About Retina Associates of Cleveland, Inc.
Retina Associates of Cleveland, Inc (RACI) is the largest retina practice in Ohio. Since 1974, the practice has striven to improve the quality of life for every patient by preserving their best vision possible. With 17 retinal specialists, 13 northeast Ohio locations, and continual clinical trials, the community has access to world-renowned expert retinal care.

About AllyGPO
AllyGPO is a tech-forward group purchasing organization empowering community practices to operate more efficiently, improve practice economics, and remain independent through AllyRetina, its dedicated retina service, and AllyIQ®, its comprehensive drug management platform combining inventory management, GPO contract optimization, and advanced analytics. www.AllyGPO.com.

About BioCareSD
BioCareSD, a BioCare company, is a national specialty distributor with over 40 years of experience delivering life-changing specialty therapies. Committed to redefining specialty distribution, BioCareSD focuses on trust, transparency, and operational excellence. The company provides high-touch, personalized service through a dedicated support team and 24/7/365 customer care. Its distribution model and expanding portfolio support partners in delivering care. www.biocaresd.com.

Media Contact:
Dara Shulman
[email protected]
866-255-9476

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/allygpo-and-biocaresd-welcome-retina-associates-of-cleveland-highlighting-the-market-need-for-new-transparent-technology-forward-options-302663422.html

SOURCE AllyGPO and BioCareSD

Market Opportunity
Stader Logo
Stader Price(SD)
$0.1567
$0.1567$0.1567
-0.57%
USD
Stader (SD) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

President Donald Trump's longtime economic adviser Kevin Hassett suggested on CNBC Wednesday that the economists at the New York Fed who produced an analysis revealing
Share
Rawstory2026/02/18 22:59
Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

President Donald Trump's Department of the Interior and its secretary, Doug Burgum, have appealed after Judge Cynthia Rufe invoked George Orwell's dystopian novel
Share
Rawstory2026/02/18 23:24
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44